The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in pharmaceuticals: coagulation factor-based compositions.  Buy the report here.

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Coagulation factor-based compositions is a key innovation area in biosimilars 

Coagulation factors also called clotting factors are blood proteins that help form blood clots on injuries to prevent bleeding. Coagulation factor concentrates are drugs used to manage bleeding in blood clotting disorders such as Haemophilia or Von Willebrand Disease. They can control, prevent, and decrease the frequency of bleeding episodes and prevent bleeding during surgery, by the activation of the prothrombin complex which induces clotting of blood. A biosimilar is a biological product that shares many characteristics with a reference biologic and doesn’t exhibit any clinically significant variations in terms of safety, purity, or potency.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of coagulation factor-based compositions. 

Key players in coagulation factor-based compositions – a disruptive innovation in the pharmaceutical industry  

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to coagulation factor-based compositions

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Sanofi 359 Unlock company profile
Novo Nordisk Foundation 267 Unlock company profile
Bayer 202 Unlock company profile
Takeda Pharmaceutical 189 Unlock company profile
Biogen 186 Unlock company profile
Moderna 184 Unlock company profile
Baxter International 180 Unlock company profile
Children's Hospital of Philadelphia 129 Unlock company profile
LFB 124 Unlock company profile
CSL 101 Unlock company profile
Catalyst Biosciences 100 Unlock company profile
Amunix Operating 97 Unlock company profile
Sangamo Therapeutics 81 Unlock company profile
Coagulant Therapeutics 51 Unlock company profile
GLAdiator Biosciences 49 Unlock company profile
Pfizer 44 Unlock company profile
Teva Pharmaceutical Industries 44 Unlock company profile
OPKO Health 37 Unlock company profile
Hanmi Science 37 Unlock company profile
DRK-Blutspendedienst Baden-Wurttemberg-Hessen 35 Unlock company profile
Johnson & Johnson 35 Unlock company profile
F. Hoffmann-La Roche 29 Unlock company profile
PDS Biotechnology 27 Unlock company profile
Nektar Therapeutics 21 Unlock company profile
Life Sciences Research Partners VZW 20 Unlock company profile
Alkermes 19 Unlock company profile
Octapharma 18 Unlock company profile
Verneuil Participations 16 Unlock company profile
Emergent BioSolutions 15 Unlock company profile
Intellia Therapeutics 15 Unlock company profile
Regeneron Pharmaceuticals 15 Unlock company profile
SK 14 Unlock company profile
ToolGen 13 Unlock company profile
Medexus Pharmaceuticals 13 Unlock company profile
Cell Machines 13 Unlock company profile
Xenetic Biosciences 13 Unlock company profile
Alveron Pharma 12 Unlock company profile
Glycotope 12 Unlock company profile
BioMarin Pharmaceutical 12 Unlock company profile
Alnylam Pharmaceuticals 12 Unlock company profile
Maxygen 12 Unlock company profile
Swedish Orphan Biovitrum 11 Unlock company profile
CNJ 11 Unlock company profile
Children's Healthcare of Atlanta 11 Unlock company profile
DRK-Blutspendedienst Ost gemeinnutzige 11 Unlock company profile
TiumBio 10 Unlock company profile
CRISPR Therapeutics 10 Unlock company profile
Beehive Capital 10 Unlock company profile
Poseida Therapeutics 9 Unlock company profile
Sigilon Therapeutics 9 Unlock company profile

Source: GlobalData Patent Analytics

Novo Nordisk is one of the leading global healthcare companies focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including haemophilia, human growth hormone (HGH) disorders, and obesity. The company has made long-term investments in novel treatments and technologies, including curative stem cell-based therapies, to continually advance the development of novel therapies. Novo Nordisk is committed to improving access to quality care for people with haemophilia and rare bleeding disorders in developing and emerging countries. It has an agreement to license 2seventy bio’s proprietary mRNA-based megaTAL™ technology for the development of a new treatment approach for haemophilia.

In terms of application diversity, Alveron Pharma is the top company, followed by Cell Machines and Swedish Orphan Biovitrum. By means of geographic reach, Moderna holds the top position. Amunix Operating and GLAdiator Biosciences are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.